Beta-D-2'-Deoxy-2'-alpha-FLUORO-2'-beta-C-SUBSTITUTED-2-Modified-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 9 of these applications claim priority to application 62/129,319, filed Mar 6, 2015. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 9,828,410 | Beta-D-2'-Deoxy-2'-alpha-FLUORO-2'-beta-C-SUBSTITUTED-2-Modified-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT In force · High confidence | Atea Pharmaceuticals, Inc. | In force | High confidence | ||
| US 10,000,523 | BETA-D-2'-Deoxy-2'-Alpha-FLUORO-2'-BETA-C-SUBSTITUTED-2-Modified-N6-SUBSTITUTED Purine Nucleotides for HCV Treatment In force · High confidence | Atea Pharmaceuticals, Inc. | In force | High confidence | ||
| US 10,005,811 | BETA-D-2'-Deoxy-2'-Alpha-FLUORO-2'BETA-C-SUBSTITUTED-2-Modified-N6-SUBSTITUTED Purine Nucleotides for HCV Treatment In force · High confidence | Atea Pharmaceuticals, Inc. | In force | High confidence | ||
| US 10,239,911 | BETA-D-2'-Deoxy-2'-Alpha-FLUORO-2'-BETA-C-SUBSTITUTED-2-Modified-N6-SUBSTITUTED Purine Nucleotides for HCV Treatment In force · High confidence | Atea Pharmaceuticals, Inc. | In force | High confidence | ||
| US 10,815,266 | BETA-D-2'-Deoxy-2'-Alpha-FLUORO-2'-BETA-C-SUBSTITUTED-2-Modified-N6-SUBSTITUTED Purine Nucleotides for HCV Treatment In force · High confidence | Atea Pharmaceuticals, Inc. | In force | High confidence | ||
| US 10,870,672 | Beta-D-2'-Deoxy-2'-Alpha-FLUORO-2'-Beta-C-SUBSTITUTED-2-Modified-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT In force · High confidence | Atea Pharmaceuticals, Inc. | In force | High confidence | ||
| US 10,870,673 | BETA-D-2'-Deoxy-2'-Alpha-FLUORO-2'-BETA-C-SUBSTITUTED-2-Modified-N6-SUBSTITUTED Purine Nucleotides for HCV Treatment In force · High confidence | Atea Pharmaceuticals, Inc. | In force | High confidence | ||
| US 10,875,885 | BETA-D-2'-Deoxy-2'-Alpha-FLUORO-2'-BETA-C-SUBSTITUTED-2-Modified-N6-SUBSTITUTED Purine Nucleotides for HCV Treatment In force · High confidence | Atea Pharmaceuticals, Inc. | In force | High confidence | ||
| US 12,084,473 | BETA-D-2'-Deoxy-2'-Alpha-FLUORO-2'-BETA-C-SUBSTITUTED-2-Modified-N6-SUBSTITUTED Purine Nucleotides for HCV Treatment In force · Low confidence | Atea Pharmaceuticals, Inc. | In force | Low confidence | ||
| Application 17/028,724 | Beta-D-2'-Deoxy-2'-Alpha-FLUORO-2'-Beta-C-SUBSTITUTED-2-Modified-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT Abandoned Abandoned Apr 9, 2022 | Atea Pharmaceuticals, Inc. | Abandoned | Abandoned Apr 9, 2022 | ||
| 2 more patents in this group · Pro | ||||||
10 of 12 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Pro members see all 12.
9 of these are in force and held by Atea Pharmaceuticals, Inc..
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.